Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Urol.

Sec. Male Urology

Volume 5 - 2025 | doi: 10.3389/fruro.2025.1641171

This article is part of the Research TopicAdvances in Pharmacological Treatments for Urogenital DisordersView all 4 articles

Integrated Management Strategies for Benign Prostatic Hyperplasia

Provisionally accepted
Yingchen ZhouYingchen Zhou1,2*Qiao LuoQiao Luo2Ruixiao WangRuixiao Wang3Dongxiang ZhengDongxiang Zheng2Yaqing XiongYaqing Xiong2Jiao ZuoJiao Zuo2Shusheng WangShusheng Wang4Liang ZhongLiang Zhong2*
  • 1Macau University of Science and Technology, Taipa, Macao, SAR China
  • 2Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China
  • 3Shenzhen Second People's Hospital, Shenzhen, China
  • 4The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

The final, formatted version of the article will be published soon.

Select one of your emails

You have multiple emails registered with Frontiers:

Notify me on publication

Please enter your email address:

If you already have an account, please login

You don't have a Frontiers account ? You can register here

Abstract Benign prostatic hyperplasia (BPH) is a common condition in aging men, leading to lower urinary tract symptoms (LUTS) that affect quality of life. Treatment options have evolved from invasive surgeries to a combination of pharmacological therapies, minimally invasive surgical therapies (MISTs), and standard surgical procedures. Medications such as α -blockers, 5-alpha reductase inhibitors (5-ARIs), and phosphodiesterase-5 inhibitors (PDE5i) are the first-line treatment for mild-to-moderate BPH, while MISTs like Rez ū m, UroLift, Aquablation, and prostatic artery embolization (PAE) provide less invasive alternatives with shorter recovery times. For larger prostates, TURP and HoLEP remain the gold standards, offering effective long-term symptom relief despite some risks. Future advancements in BPH treatment focus on robotic-assisted surgery, AI-guided treatment selection, hybrid therapies, and regenerative medicine, aiming to enhance precision, reduce complications, and improve patient outcomes. This review summarizes current BPH management strategies and explores future innovations in the field.

Keywords: Benign prostatic hyperplasia, Medications, Minimally invasive surgical therapies, LUTS (Lower urinary tract symptoms), Prostate

Received: 04 Jun 2025; Accepted: 21 Aug 2025.

Copyright: © 2025 Zhou, Luo, Wang, Zheng, Xiong, Zuo, Wang and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Yingchen Zhou, Macau University of Science and Technology, Taipa, Macao, SAR China
Liang Zhong, Zhongshan Hospital of Traditional Chinese Medicine, Zhongshan, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Supplementary Material